Carbon Medical Technologies : Biocompatible Innovations for Urology Implants

In an era of significant reevaluation of treatments for stress urinary incontinence (SUI) due to suboptimal options, including the use of pessary devices, bladder training, pelvic floor exercises, and dietary modifications that do not offer lasting relief to patients, combined with the uncertainty surrounding the use of surgical mesh slings, patients and physicians are seeking alternatives, including more permanent and infallible solutions that can address the challenges of SUI. However, they need not seek any further. Carbon Medical Technologies (CMT), an R&D and implantable medical devices manufacturing company, leverages its proprietary pyrolytic carbon coating technology to develop industry-leading products for minimally invasive applications. One of CMT’s flagship products is the injectable bulking agent Durasphere for the treatment of SUI, containing pyrolytic carbon-coated graphite beads suspended in a waterbased carrier gel. It is one of the most efficient treatments for SUI caused by intrinsic sphincter deficiency (ISD). Durasphere helps obtain closure from the bladder neck to mid-urethra and prevents urine leakage. It is an officebased procedure, done under local anesthesia, and can be administered in about 15 minutes, allowing the patient to be more comfortable and physicians more efficient with their time. “With over 20 years of R&D expertise, we have created tools and training, including the proprietary ‘Bent Needle’ periurethral injection approach, which simplifies injection and contributes to positive patient outcomes,” states Stephanie Kent, the President and CEO at CMT. In fact, Durasphere can be implanted into patients using both transurethral and periurethral methods, providing the versatility that allows physicians the option to use their preferred approach while performing the procedure. In addition, Durasphere is a low-cost, safe, and effective option, with appropriate provider reimbursement, for treating patients with SUI due to ISD.

CMT also developed a complete line of implantable carbon-coated fiducial markers (BiomarC) to address the challenges often encountered in radiation treatment of prostate cancer. The BiomarCfiducial markers offer clear visual images deciphering healthy tissues from the radiation target area allowing for rapid and more precise radiation treatment planning. The unique carbon coating in combination with the core materials of these markers are compatible with all forms of radiation therapy and can be seamlessly used for IGRT/IMRT, proton therapy, CT, MRI, and portal imaging.